非小细胞肺癌患者ERCC1,β-tubulin Ⅲ的表达与TP/NP方案化疗敏感性关系分析
被引量:5
ERCC1 and Class Ⅲ β-tubulin Protein Expression in Relation to Tumour Response and Survival of Stage ⅢB/Ⅳ NSCLC Patients Treated with TP/NP Chemotherapy Regimens
摘要
近20年来,随着第3代化疗新药(异长春花碱、紫杉类和吉西他滨等)在临床的广泛应用,以铂类为基础联合第3代化疗新药的方案已成为非小细胞肺癌(NSCLC)病人的标准化疗(SC)方案,但是化疗的反应率(RR)、总生存时间(OS)和肿瘤进展时间(TTP)仍然很低,而且不同NSCLC病人对同一种标准化疗方案疗效差异很大。
出处
《中国肺癌杂志》
CAS
2009年第1期82-85,共4页
Chinese Journal of Lung Cancer
参考文献6
-
1Seve P,Dumontet C.Chemoresistance in non-small cell lung cancer.Curr Med Chem Anticancer Agents,2005,5(1):73-88.
-
2Seve P,Mackey J,Isaac S,et al.Class Ⅲ beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel.Mol Cancer Ther,2005,4(12):2001-2007.
-
3Wachtersa FM,Wongb LSM,Timensc W,et al.ERCC1,hRad51 and BRCA1 protein expression in relation to tumour response and survival of stage Ⅲ/Ⅳ NSCLC patients treated with chemotherapy.Lung Cancer,2005,50(2):211-219.
-
4Rosell R,Taron M,Barnadas A,et al.Nucleotide excision repair pathways involved in cisplatin resistance in non-small cell lung cancer.Cancer Control,2003,10 (4):297-305.
-
5Urano N,Fujiwara Y,Doki Y,et al.Clinical significance of class-Ⅲ beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer,Int Oncol,2006,28(2):375-381.
-
6Seve P,Lai R,Ding K,et al.Class Ⅲβ -tubulin expression and benefit from adjuvant Cisplatin/Vinorelbine chemotherapy in operable nonsmall cell lung cancer:Analysis of NCIC JBR.10.Clin Cancer Bes,2007,13(3):994-999.
同被引文献44
-
1Paul E.VAN SCHIL Michèle DE WAELE Jeroen M.HENDRIKS Patrick R.LAUWERS.Is there a role for surgery in stage ⅢA-N2 non-small cell lung cancer?[J].中国肺癌杂志,2008,11(5):615-621. 被引量:14
-
2袁芃,缪小平,张雪梅,王中华,谭文,张湘茹,孙燕,徐兵河,林东昕.核苷酸切除修复系统基因遗传多态与晚期非小细胞肺癌患者铂类药物敏感性关系[J].癌症,2005,24(12):1510-1513. 被引量:46
-
3Ikeda S, Takabe K, Suzuki K. Expression of ERCC1 and class Ⅲβ tubulin for predicting effect of Caboplatin/Paclitaxel in patients with advanced inoperable non-small cell lung cancer [ J ]. Pathol Int, 2009,59 (12) : 863-867.
-
4Hayashi Y, Kuriyama H, Umezu H, et al. Class Ⅲ betatubulin expression in tumor cells is correlated with resistance to Docetaxel in patients with completely reseeted non-small-cell lung cancer [J]. Inter Med, 2009,48(4):203-208.
-
5Seve P, Lai R, Ding K, et al. Class Ⅲ beta-tubulin expression and benefit from adjuvant Cisplatin/Vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of NCIC JBR. 10 [J]. Clin Cancer Res, 2007,13(3) :994-999.
-
6Koh Y, Jang B, Han SW, et al. Expression of class Ⅲ beta- tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer [J].J Thorac Oncol, 2010,5 (3) : 320-325.
-
7Kamath K, Wilson L, Cabral F, et al. beta Ⅲ-tubulin induces Paclitaxel resistance in association with reduced effects on microtubule dynamic instability [J]. J Biol Chem, 2005,280 (13) : 12902-12907.
-
8Hari M, Yang H, Zeng C, et al. Expression of class Ⅲ betatubulin reduces microtubule assembly and confers resistance to Paclitaxel [J ]. Cell Motil Cytoskeleton, 2003,56( 1 ):45-56.
-
9Kavallaris M, Tait AS, Walsh B J, et al. Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells [J ]. Cancer Res, 2001,61 (15) :5803- 5809.
-
10Seve P, Reiman T, Dumontet C. The role of βⅢ tubulin in predicting chemoresistance in non-small cell lung cancer [J]. Lung Cancer, 2010,67(2) : 136-143.
引证文献5
-
1沈红,蔡健康,沈立,崔进,王虹.晚期非小细胞肺癌β-微管蛋白Ⅲ表达与抗微管药敏感性Meta分析[J].循证医学,2011,11(2):102-106. 被引量:8
-
2冷雪峰,冼磊,陈铭伍,李满红.非小细胞肺癌组织中ERCC1基因的表达及临床意义[J].广西医学,2011,33(5):540-543. 被引量:2
-
3郭卫东,张惠洁,包立峰.支气管动脉灌注化疗治疗非小细胞肺癌的疗效及血清相关因子变化的研究[J].临床肿瘤学杂志,2013,18(3):207-211. 被引量:3
-
4李昊,钟理,丁浩,沈志高.肺癌个体化治疗的现状及展望[J].临床与实验病理学杂志,2014,30(2):196-199. 被引量:13
-
5刘东声.非小细胞肺癌NP方案化疗敏感性与DNA修复基因XRCC1多态性的关系研究[J].当代医药论丛,2014,12(15):210-211. 被引量:1
二级引证文献27
-
1齐全,赵文英.转移性非小细胞肺癌的化学治疗现状与进展[J].中国临床药理学与治疗学,2012,17(5):573-581. 被引量:5
-
2张毅,郑玲.非小细胞肺癌耐药相关因子与个体化治疗的研究进展[J].现代临床医学,2012,38(3):165-168.
-
3李敏,樊赛军.BRCA1:一种新的非小细胞肺癌放化疗疗效的预测基因[J].中国肺癌杂志,2012,15(8):481-490. 被引量:4
-
4李艳,郭其森.βⅢ-tubulin在NSCLC中的表达与抗微管类药物耐药相关性的研究进展[J].中华肺部疾病杂志(电子版),2013,6(2):71-75. 被引量:7
-
5郭沁香.晚期非小细胞肺癌患者吉西他滨化疗疗效及毒性相关基因多态性的研究[J].中国基层医药,2013,20(22):3377-3378. 被引量:1
-
6陈庆恺,柳青,丁艳辉,吴亚梅,冯燕梅.β-微管蛋白Ⅰ基因突变与多烯紫杉醇治疗晚期非小细胞肺癌耐药的相关性研究[J].重庆医科大学学报,2013,38(9):1017-1021.
-
7隋丹,姜丽岩.ERCC1在非小细胞肺癌患者中血液和肿瘤组织中表达的相关性研究[J].医药论坛杂志,2013,34(12):1-5.
-
8阳诺,马辉,冼磊,陈铭伍.BRCA1、RRM1和TUBB3基因在非小细胞肺癌中的表达及其与化疗的关系[J].微创医学,2014,9(4):389-393. 被引量:2
-
9韩其正,曹望凯,王永明.灌注化疗联合碳酸氢钠与单纯支气管动脉灌注化疗治疗非小细胞肺癌的疗效分析[J].医学临床研究,2018,35(12):2467-2468. 被引量:6
-
10杨云辉.64排螺旋CT诊断早期中心型肺癌的临床效果[J].中国医学物理学杂志,2015,32(3):429-431. 被引量:23
-
1于丁.晚期大肠癌的标准化疗方案有待进一步研究[J].中华医学杂志,2002,82(13).
-
2贾立群,朱世杰,李佩文,张克俭,万冬桂,蔡光蓉,侯梅英.艾迪注射液联合顺铂、5-氟尿嘧啶治疗胃癌的疗效观察[J].中华肿瘤杂志,2003,25(5):517-517. 被引量:17
-
3张慕娟,劳炳慰,赵斌,周素珠.放射并化学疗法对局部晚期非小细胞肺癌的效果[J].齐鲁医学杂志,2003,18(1):58-59. 被引量:1
-
4王静,阎瑞峰.紫杉醇联合卡铂或奥沙利铂治疗晚期非小细胞肺癌的临床疗效观察[J].山西医药杂志,2015,44(13):1546-1548. 被引量:8
-
5刘静.CAG方案治疗老年急性髓系白血病30例临床观察[J].中国现代医生,2012,50(5):120-121. 被引量:17
-
6童永平,肖桂枝.135例胃癌与幽门螺杆菌感染关系分析[J].四川医学,2000,21(1):71-71.
-
7海镇环,胡成平.1186例肺癌与吸烟的关系分析[J].湖南医科大学学报,1992,17(3):273-275. 被引量:1
-
8刘飒,智连艺,张伟.FOLFOX4方案治疗晚期大肠癌36例临床观察[J].山东医药,2007,47(13):46-46. 被引量:2
-
9宋泽江.CAG方案治疗急性髓系白血病的临床观察[J].中国医药指南,2014,12(22):265-266. 被引量:4
-
10花慧莲.雷替曲塞联合奥沙利铂治疗结直肠癌临床分析[J].现代中西医结合杂志,2015,24(33):3720-3721. 被引量:4